Ebrahim Umer: The Sickest Liver Patients Deserve One Language – Lessons from the Kyoto Consensus
Ebrahim Umer, Gastroenterology and Hepatology Fellow at St. Paul’s Hospital Millennium Medical College, shared a post on LinkedIn:
“The Sickest Liver Patients Deserve One Language – Lessons from the Kyoto Consensus
One of the most important challenges in modern hepatology is that two clinicians may look at the same patient with advanced chronic liver disease and arrive at different diagnoses of Acute-on-Chronic Liver Failure (ACLF) depending on which international criteria they follow.
The concept of ACLF has transformed our understanding of liver decompensation. It is no longer viewed simply as worsening cirrhosis, but rather as a distinct syndrome characterized by acute deterioration, systemic inflammation, organ failure, and high short-term mortality.
Yet, despite its clinical importance, a universal definition remains elusive.
Today, three major societies continue to use different diagnostic frameworks:
- EASL-CLIF focuses heavily on extrahepatic organ failures and grades ACLF according to the number of failed organs.
- APASL emphasizes acute hepatic insult leading to jaundice and coagulopathy, followed by ascites and/or encephalopathy within a defined time frame.
- NACSELD primarily evaluates extrahepatic organ failures in hospitalized patients with cirrhosis.
As a result, the same patient may be classified as ACLF by one society and not by another. This diagnostic heterogeneity affects epidemiology, clinical decision-making, transplant prioritization, research outcomes, and even communication among hepatologists worldwide.
Beyond definitions lies a human reality.
The patient in front of us is not an EASL patient, an APASL patient, or a NACSELD patient. They are a critically ill individual whose prognosis can change dramatically within days. Delayed recognition may mean missed opportunities for intensive management, liver transplantation, or life-saving interventions.
This is why ongoing international efforts toward harmonization are so important.
The emerging Kyoto Consensus represents a significant step toward bridging Eastern and Western perspectives on ACLF. Rather than focusing on differences, it seeks common ground—acknowledging the diverse pathophysiologic pathways of ACLF while moving the field closer to a globally accepted framework for diagnosis, prognostication, and management.
As hepatologists, our ultimate goal is not merely to define ACLF better, but to identify it earlier, treat it more effectively, and improve survival for some of the sickest patients we care for.”
Stay updated with Hemostasis Today.
-
Sep 3, 2026, 00:03Jochebed Adwoa Sutherland: First Reported Case of Breast Mondor’s Disease in a Patient Living with Sickle Cell
-
Sep 2, 2026, 23:50Shashank Joshi: Individualized vs. Standard BP Control Shows Similar 90-Day Outcomes
-
Sep 2, 2026, 18:26Strengthening Comprehensive Care for Inherited Bleeding Disorders in Ecuador – World Federation of Hemophilia
-
Sep 2, 2026, 18:24Zeeshan Ahmed Khattak: Managing Febrile Neutropenia in Hematology/Oncology and Transplant Patients
-
Sep 2, 2026, 18:22Mark Heyland: The Role of Thromboinflammation in Fracture Non-Union
-
Sep 2, 2026, 18:18Katie Gonzalez: Understanding the Hidden Risk of Inherited Thrombophilias
-
Sep 2, 2026, 18:14Beruni Narmada W: Rare Basal Vein of Rosenthal Thrombosis Presenting With Thalamic Haemorrhage
-
Sep 2, 2026, 18:03Omnia Ahmed: Effect of Hematocrit (HCT) on Coagulation Testing
-
Sep 2, 2026, 17:44John Thymis: Five E-Posters Presented at ESC Congress 2026 in Munich